Pharmacy Board orders withholding of drug used to relieve menstrual pain over contamination concerns

The Pharmacy and Poisons Board (PPB) announced the move on Wednesday, after detecting suspected contamination with Diethylene Glycol (DEG) and Ethylene Glycol (EG) at levels exceeding acceptable limits.
The government has ordered the immediate withholding of Mefnac Oral Suspension (Mefenamic Acid 50mg/5ml) manufactured by Efroze Chemical Industries Pvt Ltd, Pakistan.
The Pharmacy and Poisons Board (PPB) announced the move on Wednesday, after detecting suspected contamination with Diethylene Glycol (DEG) and Ethylene Glycol (EG) at levels exceeding acceptable limits.
More To Read
- KMPDC launches 2026 licence renewal for doctors, health facilities
- Pharmacy and Poisons Board flags falsified batch of Avastin (Bevacizumab 100 mg)
- Pharmacy board dismisses claims of medicine import ban, says drug supply uninterrupted
- Drug shortage fears mount as distributors push for reinstatement of 21,000 blocked medicines
- Pharmacy and Poisons Board assures paracetamol use during pregnancy safe
- Pharmacy board warns Kenyans against off-label use of Ozempic for weight loss
Mefnac Oral Suspension, containing Mefenamic Acid, is commonly used to treat mild to moderate pain, including menstrual pain, and to reduce inflammation and fever. However, the suspected contamination of this product with harmful substances has raised significant safety concerns.
In its directive, the PPB instructed all pharmaceutical outlets, healthcare facilities, and professionals, as well as the public, to cease distribution, sale, issuance, and use of the product until further notice.
The board emphasised that failure to comply with the order could pose serious health risks to patients.
The PPB also encouraged healthcare professionals and members of the public to report any cases of substandard medicines or adverse drug reactions.
The cases can be reported through their various channels including their online portal:https://pv.pharmacyboardkenya.org/users/mpublic or use USSD code: Mobile application: mPvERS (available on Android and iOS).
Cases can also be channelled to their email: [email protected] or [email protected] or telephone number: 0795743049.
The board reaffirmed its commitment to ensuring the safety and efficacy of medicines in the market, urging vigilance to protect public health.
Top Stories Today